LiGeR-HN phase III trials of petosemtamab + pembrolizumab and petosemtamab monotherapy in recurrent or metastatic HNSCC.

Machiels JP, Fayette J, Haddad R, Adkins D, Gillison M, Harrington KJ, Kim SB, Le Tourneau C, Psyrri A, Rosenberg A, Siu LL, Tahara M, William WN Jr, Ford J, Jauhari S, Pyle R, Shen YM, Yao D, Zohren F, Vokes E

Open source

DOI: 10.1080/14796694.2025.2511470
Published: 2025 Jul
Container: Future oncology (London, England)
Publisher: Not recorded
Open access: yes

Credibility signals

limited evidence Score 45/100 under policy 1.0.0. This is a metadata assessment, not a judgment of the paper's conclusions.

Show all credibility signals

cautionDOI registered: No matching Crossref record was present in this response. Source: Crossref; license: CC0 metadata
cautionDOI resolves: No matching Crossref record was present in this response. Source: Crossref; license: CC0 metadata
not scoredDirectory of Open Access Journals: No matching DOAJ record was present in this response. No allow-list match; this is not evidence of low credibility. Source: DOAJ; license: CC0
not scoredMEDLINE indexed: Not checked or no result supplied; no credibility inference made. Source: No authority result supplied; license: Unknown
not scoredOpenAlex core source: Not checked or no result supplied; no credibility inference made. Source: No authority result supplied; license: Unknown
not scoredKnown publisher allow-list: Not checked or no result supplied; no credibility inference made. Source: No authority result supplied; license: Unknown
not scoredROR affiliation: Not checked or no result supplied; no credibility inference made. Source: No authority result supplied; license: Unknown
not scoredRetraction Watch retraction: No retraction notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete. Source: Retraction Watch; license: CC BY 4.0
not scoredRetraction Watch expression of concern: No expression of concern notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete. Source: Retraction Watch; license: CC BY 4.0
not scoredRetraction Watch correction: No correction notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete. Source: Retraction Watch; license: CC BY 4.0
not scoredRetraction Watch reinstatement: No reinstatement notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete. Source: Retraction Watch; license: CC BY 4.0
supportingOpen access status: Normalized open-access status: open. Source: Normalized work metadata; license: Caller-provided; provenance license not supplied to scorer
not scoredPublication license: Not checked or no result supplied; no credibility inference made. Source: No authority result supplied; license: Unknown
not scoredPublication version: A publication version was supplied but is not scored. Source: Normalized work metadata; license: Caller-provided; provenance license not supplied to scorer
cautionMetadata completeness: 5 of 6 scored descriptive metadata groups are present; missing fields increase uncertainty. Source: Normalized work metadata; license: Caller-provided; provenance license not supplied to scorer

Cite this work

BibTeX

@article{allodium:10.1080/14796694.2025.2511470,
  title = {LiGeR-HN phase III trials of petosemtamab + pembrolizumab and petosemtamab monotherapy in recurrent or metastatic HNSCC.},
  author = {Machiels JP and Fayette J and Haddad R and Adkins D and Gillison M and Harrington KJ and Kim SB and Le Tourneau C and Psyrri A and Rosenberg A and Siu LL and Tahara M and William WN Jr and Ford J and Jauhari S and Pyle R and Shen YM and Yao D and Zohren F and Vokes E},
  year = {2025},
  journal = {Future oncology (London, England)},
  doi = {10.1080/14796694.2025.2511470},
  url = {https://doi.org/10.1080/14796694.2025.2511470}
}

RIS

TY  - JOUR
TI  - LiGeR-HN phase III trials of petosemtamab + pembrolizumab and petosemtamab monotherapy in recurrent or metastatic HNSCC.
AU  - Machiels JP
AU  - Fayette J
AU  - Haddad R
AU  - Adkins D
AU  - Gillison M
AU  - Harrington KJ
AU  - Kim SB
AU  - Le Tourneau C
AU  - Psyrri A
AU  - Rosenberg A
AU  - Siu LL
AU  - Tahara M
AU  - William WN Jr
AU  - Ford J
AU  - Jauhari S
AU  - Pyle R
AU  - Shen YM
AU  - Yao D
AU  - Zohren F
AU  - Vokes E
PY  - 2025
JO  - Future oncology (London, England)
DO  - 10.1080/14796694.2025.2511470
UR  - https://doi.org/10.1080/14796694.2025.2511470
ER  -

APA

JP, M., J, F., R, H., D, A., M, G., KJ, H., SB, K., C, L. T., A, P., A, R., LL, S., M, T., Jr, W. W., J, F., S, J., R, P., YM, S., D, Y., F, Z., & E, V. (2025). LiGeR-HN phase III trials of petosemtamab + pembrolizumab and petosemtamab monotherapy in recurrent or metastatic HNSCC.. Future oncology (London, England). https://doi.org/10.1080/14796694.2025.2511470

Source records

pubmed · retrieved 2026-11-10T15:14:22.743Z